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Abstract 
With the advancement of treatment modalities in radiation therapy for cancer patients, 
outcomes have improved, but at the cost of increased treatment plan complexity and 
planning time. The accurate prediction of dose distributions would alleviate this issue by 
guiding clinical plan optimization to save time and maintain high quality plans. We have 
modified a convolutional deep network model, U-net (originally designed for segmentation 
purposes), for predicting dose from patient image contours of the planning target volume 
(PTV) and organs at risk (OAR). We show that, as an example, we are able to accurately 
predict the dose of intensity-modulated radiation therapy (IMRT) for prostate cancer 
patients, where the average Dice similarity coefficient is 0.91 when comparing the predicted 
vs. true isodose volumes between 0% and 100% of the prescription dose. The average value 
of the absolute differences in [max, mean] dose is found to be under 5% of the prescription 
dose, specifically for each structure is [1.80%, 1.03%](PTV), [1.94%, 4.22%](Bladder), 
[1.80%, 0.48%](Body), [3.87%, 1.79%](L Femoral Head), [5.07%, 2.55%](R Femoral Head), 
and [1.26%, 1.62%](Rectum) of the prescription dose.  We thus managed to map a desired 
radiation dose distribution from a patient’s PTV and OAR contours. As an additional 
advantage, relatively little data was used in the techniques and models described in this 
paper. 
 
  
1 Introduction 
Radiation therapy has been one of the leading treatment methods for cancer patients, and 
with the advent and advancements of innovative modalities, such as intensity modulated 
radiation therapy (IMRT)1-7 and volume modulated arc therapy (VMAT)8-14, plan quality has 
drastically improved over the last few decades. However, such a development comes at the 
cost of treatment planning complexity. While this complexity has given rise to better plan 
quality, it can be a double-edged sword that increases the planning time and obscures the 
tighter standards that these new treatment modalities are capable of meeting. This has 
resulted in greatly increased clinical treatment planning time, where the dosimetrist goes 
through many iterations to adjust and tune treatment planning parameters, as well as 
receiving feedback from the physician many times before the plan is approved. Many further 
developments in treatment planning algorithms have aided in reducing the treatment 
complexity, such as including dose-volume constraints in a feasibility seeking algorithm15, 
creation of many Pareto surface plans for the planner to navigate through16-18, and many 
others for performance improvements and usage simplification19-25. However, using any of 
these algorithms still requires intelligent inputs or tweaks from the human planner, such as 
weight tuning, deciding appropriate DVH constraints or determining appropriate tradeoffs. 
To reduce the planning complexity even further, the prediction of dose distributions and 
constraints has become an active field of research, with the goal of creating consistent plans 
that are informed by the ever-growing body of treatment planning knowledge, as well as 
guiding clinical plan optimization to save time and to maintain high quality treatment plans 
across planners of different experiences and skill levels. Figure 1A shows the typical 
treatment planning workflow with many iterations for the dosimetrist and physician, and 
Figure 1B shows the workflow with a dose prediction model in place. Overall workflow does 
not change, but we expect the number of iterations to considerably decrease. 
 
Figure 1: A) Current treatment planning workflow. B) Proposed workflow with AI-based 
dose prediction. Less iterations denoted as dotted-blue lines. TPS = treatment planning 
system. 
Much of the work for dose prediction in radiotherapy has been revolving around a paradigm 
known as knowledge-based planning (KBP)26-38, which has been focused on the prediction 
of a patient’s dose volume histogram (DVH) and dose constraints, using historical patient 
plans and information. While KBP has seen large successes and advancements that have 
improved the reliability of its predictions, these methods require the enumeration of 
parameters/features in order to feed into a model for dose and DVH prediction. Although 
much time and effort has been spent in selecting handcrafted features—such spatial 
information of organs at risk (OAR) and planning target volumes (PTV), distance-to-target 
histograms (DTH), overlapping volume histograms (OVH), structure shapes,  number of 
delivery fields, etc.31-39—it is still deliberated as to which features have the greatest impact 
and what other features would considerably improve the dose prediction. Artificial neural 
networks have been applied to learn more complex relationships between the handcrafted 
data31, but it is still limited by the inherent information present in that data. Another known 
KBP approach by Good et al.40, approached the problem by creating a “knowledge database” 
of 132 prostate treatment plans. A new patient is then matched to one of the knowledge 
database patient using mutual information as a similarity metric, the database patient’s plan 
parameters are adapted and optimized to the new patient. The success of such a method 
relies on the size and diversity of its patients, and may possibly be limited when faced with 
more complex treatment sites, such as head and neck cancer patient. 
In the last few years, deep learning has made a quantum leap in the advancement of many 
areas. One particular area was the progression of convolutional neural network (CNN)41 
architectures for imaging and vision purposes42-44. In 2015, fully convolutional networks 
(FCN)45 were proposed, and outperformed state-of-the-art techniques of its time at semantic 
segmentation. Shortly after, more complex models were built around the FCN concept in 
order to solve some of its shortcomings. One particular architecture that was proposed is a 
model called U-net46, which focused on the semantic segmentation on biomedical images. 
There were three central ideas in the U-net’s architecture design: 1) a large number of max 
pooling operations to allow for the convolution filters to find global, non-local features, 2) 
transposed convolution operations—also known as deconvolution47 or up-convolution46—
to return the image to its original size, and 3) copying the maps from the first half of the U-
net in order to preserve the lower-level, local features. While inserting some domain 
knowledge into the problem may be helpful due to a limited amount of data, we look towards 
deep learning to reduce our dependence on handcrafted features, and allow the deep 
network to learn its own features for prediction. Even though the U-net and other FCN 
architectures were designed for the task of image segmentation, we hypothesize that, with 
some innovative modifications, the U-net architecture will be able to accurately predict a 
voxel-level dose distribution simply from patient contours, by learning to abstract its own 
high-level local and broad features. Our motivation is two-fold: 1) (short term motivation) 
to provide guidance for the dosimetrist during clinical plan optimization in order to improve 
the plan quality and uniformity and, to reduce the total planning time by decreasing the 
number of iterations the dosimetrist has to go through with the physician and treatment 
planning optimization, and 2) (long term motivation) to eventually develop an artificial 
intelligent treatment planning tool, capable of creating entire clinically acceptable plans. 
2 Methods 
2.1 U-net architecture for dose prediction 
 
Figure 2: Schematic of an example U-net architecture with additional CNN layers used for 
dose prediction. The numbers above the boxes represent the number of features for each 
map, while the numbers to the left of each hierarchy in the U-net represents the size of each 
2D feature. 
As shown in Figure 2, we constructed a seven-level hierarchy U-net, with  some innovative 
modifications made on the original design achieve the goal of contour-to-dose mapping. The 
input starts with 6 channels of 256 x 256 pixel images. Specifics of the input data is outlined 
in Section 2.2. The choice for 7 levels with 6 max pooling operations was made to reduce the 
feature size from 256 x 256 pixels down to 4 x 4 pixels, allowing for the 3 x 3 convolution 
operation to connect the center of the tumor to the edge of the body for all of the patient 
cases. Zero padding was added to the convolution process so that the feature size is 
maintained. Seven CNN layers, denoted with the purple arrows in Figure 2, were added after 
the U-net in order to smoothly reduce the number of filters to one, allowing for high precision 
prediction. Batch normalization48 (BN) was added after the convolution and rectified linear 
unit (ReLU) operations in the U-net, which allows for a more equal updating of the weights 
throughout the U-net, leading to faster convergence. It should be noted that the original BN 
publication suggests performing the normalization process before the non-linearity 
operation, but we had found better performance using normalization after the ReLU 
operation—the validation’s mean squared error after 10 epochs was 0.3528 for using BN 
before ReLU and 0.0141 for using BN after ReLU.  
 
Figure 3: Dropout scheme implemented for the U-net and CNN layers 
To prevent the model from over-fitting, dropout49 regularization was implemented 
according to the scheme shown in Figure 3, which is represented by the equation: 
𝑑𝑟𝑜𝑝𝑜𝑢𝑡𝑟𝑎𝑡𝑒 = 𝑟𝑎𝑡𝑒𝑚𝑎𝑥 × (
𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑖𝑙𝑡𝑒𝑟𝑠
max 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑖𝑙𝑡𝑒𝑟𝑠
)
1
𝑛⁄
. For our setup, we chose 𝑟𝑎𝑡𝑒𝑚𝑎𝑥 =
0.25 and the 𝑚𝑎𝑥 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑖𝑙𝑡𝑒𝑟𝑠 = 1536.  We chose 𝑛 = 4  for the U-net layers, and 𝑛 =
2 for the added CNN layers. The choice for the dropout parameters was determined 
empirically, until the gap between the validation loss and training loss did not tend to 
increase during training. 
The Adam algorithm50 was chosen as the optimizer to minimize the loss function. We used a 
learning rate of 1 × 10−4,  and the default Adam parameters 𝛽1 = 0.9, 𝛽2 = 0.999, and 
𝑑𝑒𝑐𝑎𝑦 = 0. In total, the network consisted of 46 layers. The deep network architecture was 
implemented in Keras51 with Tensorflow52 as the backend. 
 
2.2 Training and Evaluation 
To test the feasibility of this model, treatment plans of 88 clinical coplanar IMRT prostate 
patients, each planned with 7 IMRT fields at 15 megavolts (MV), were used. The 7 IMRT beam 
angles were similar across the 88 patients. Each patient had 6 contours: planning target 
volume (PTV), bladder, body, left femoral head, right femoral head, and rectum. The volume 
dimensions were reduced to 256 x 256 x 64 voxels, with resolutions of 2 x 2 x 2.5 mm3. For 
training, all patient doses were normalized such that the mean dose delivered to the PTV was 
equal to 1. 
The U-net model was trained on single slices of the patient. As input, the 6 contours were 
each treated as their own channel in the image (analogous to how RGB images are treated as 
3 separate channels in an image). The output is the U-net’s prediction of the dose for that 
patient slice. The loss function was chosen to be the mean squared error between the 
predicted dose and the true dose delivered to the patient. 
Since the central slices containing the PTV were far more important than the edge slices for 
dose prediction, we implemented a Gaussian sampling scheme—the center slice would more 
likely be chosen when the training function queried for another batch of random samples. 
The distance from the center slice to the edge slice was chosen to equal 3 standard deviations 
for the Gaussian sampling. 
 
Figure 4: Schematic for 10-fold cross-validation. A test set is held out from the cross 
validation procedure, and is used to test the best performance model. 
To assess the overall performance of the model, 8 patients were selected as a test set, and 
then 10-fold cross-validation procedure was performed on the remaining 80 patients, as 
shown in Figure 4. Each of the 10 folds divides the remaining 80 patients into 72 training 
patients and 8 validation patients. Ten separate U-net models are initialized, trained, and 
validated on a unique training and validation combination. Each fold produces a model that 
can predict a dose distribution from contours. From these 10 trained models, we then take 
the best performance model, based on its validation loss, and evaluate this model on the test 
set. 
For the remainder of the manuscript, some common notation will be used. 𝐷# is the dose 
that #% of the volume of a structure of interest is at least receiving. 𝑉𝑅𝑂𝐼 is the volume of the 
region of interest. For example, 𝐷95 is the dose that 95% of the volume of the structure of 
interest is at least receiving. 𝑉𝑃𝑇𝑉 is the volume of the PTV and 𝑉#%𝐼𝑠𝑜 is the volume of the 
#% isodose region. Isodose volumes are binary masks defined as 1 if the voxel contains a 
dose value above some threshold and 0 otherwise. The #% is the threshold for the isodose 
volume calculation and represents a percent of the prescription dose. 
To equally compare across the patients, all plans were normalized such that 95% of the PTV 
volume was receiving the prescription dose (𝐷95). This normalization is applied to both the 
dose in the test set and to the dose prediction of the network, and was done by multiplying 
the dose with ratio 
𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑑𝑜𝑠𝑒
𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑑𝑜𝑠𝑒 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑡𝑜 95% 𝑜𝑓 𝑃𝑇𝑉
. It should be noted that this is normalized 
differently than for training the model, which had normalized the plans by PTV mean dose. 
Normalizing by PTV mean dose creates a uniform dataset which is more likely to be stable 
for training, but plans normalized by D95 have more clinical relevance and value for 
assessment. All dose statistics will also be reported relative to the prescription dose (i.e. the 
prescription dose is set to 1). As evaluation criteria, Dice similarity coefficients (
2(𝐴 ∩ 𝐵)
𝐴+𝐵
) of 
isodose volumes, structure mean and max doses, PTV 𝐷98, 𝐷99, 𝐷𝑚𝑎𝑥 , PTV homogeneity 
(
𝐷2−𝐷98
𝐷50
), van’t Riet conformation number53 (
(𝑉𝑃𝑇𝑉 ∩ 𝑉100%𝐼𝑠𝑜)
2
𝑉𝑃𝑇𝑉 × 𝑉100%𝐼𝑠𝑜
), and the dose spillage 𝑅50 
(
𝑉50%𝐼𝑠𝑜
𝑉𝑃𝑇𝑉
), were evaluated. 
Five NVIDIA Tesla K80 dual-GPU graphics cards (10 GPU chips total) were used in this study. 
One GPU was used for training each fold of the 10-fold cross-validation. Training batch size 
was chosen to be 24 slices. The datasets generated during and/or analyzed during the 
current study are not publicly available due to sensitive medical information but are 
available from the corresponding author on reasonable request. Usage of the patient data 
has been approved by the UT Southwestern Protocol Review and Monitoring Committee 
(PRMC) and the Institutional Review Board (IRB). All patient data has been fully 
anonymized, and all methods were performed in accordance with the relevant guidelines 
and regulations outlined by the institution. Since gathered patient data was retrospective 
and did not directly involve the human participants during the study, informed consent is 
not applicable to this study. 
 
3 Results 
 
Figure 5: Plot of train vs. validation loss as a function of epochs from one of the folds. 
In total, models from all folds trained for 1000 epochs each, which took approximately 6 days 
on the 10 GPUs. A plot of training and validation loss from one of the folds is shown in Figure 
5 as an example. The final average loss ± standard deviation between all the folds is 
(1.02 ± 0.05) × 10−4 (training loss) and (6.26 ± 1.34) × 10−4 (validation loss). Of the 10 
folds, the model from the 5th fold performed the best with the lowest validation loss of 4.47 ×
10−4. This model was used to evaluate the dosimetric performance on the test set of patients. 
 
 
Average Absolute Dose Difference     |
𝐷𝑇𝑟𝑢𝑒−𝐷𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛
𝐷𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛
| × 100 
mean value ± standard deviation 
Cross-Validation Results Test Results 
𝐷𝑚𝑎𝑥  𝐷𝑚𝑒𝑎𝑛  𝐷𝑚𝑎𝑥  𝐷𝑚𝑒𝑎𝑛 
PTV 1.41 ± 1.13 0.77 ± 0.58 1.80 ± 1.09 1.03 ± 0.62 
Bladder 1.38 ± 1.17 2.38 ± 2.26 1.94 ± 1.31 4.22 ± 3.63 
Body 1.45 ± 1.21 0.86 ± 0.42 1.80 ± 1.09 0.48 ± 0.35 
L Fem Head 2.46 ± 2.56 1.16 ± 0.74 3.87 ± 3.26 1.79 ± 1.58 
R Fem Head 2.42 ± 2.45 1.17 ± 0.88 5.07 ± 4.99 2.55 ± 2.38 
Rectum 1.34 ± 1.02 1.39 ± 1.03 1.26 ± 0.62 1.62 ± 1.07 
Table 1: Average differences in mean and max dose with standard deviations. 
 
 PTV Statistics, van’t Riet Conformation Number, and Dose Spillage 
 mean value ± standard deviation 
 Cross-Validation Results Test Results 
 True Values Pred Values True - Pred True Values Pred Values True - Pred 
PTV D98 0.98 ± 0.01 0.98 ± 0.01 -0.00 ± 0.01 0.98 ± 0.01 0.98 ± 0.01 0.00 ± 0.00 
PTV D99 0.97 ± 0.01 0.97 ± 0.04 0.00 ± 0.04 0.96 ± 0.01 0.97 ± 0.01 0.00 ± 0.01 
PTV 𝐷𝑚𝑎𝑥  1.08 ± 0.02 1.08 ± 0.02 0.01 ± 0.02 1.08 ± 0.01 1.07 ± 0.02 0.01 ± 0.02 
PTV 
Homogeneity 
0.09 ± 0.02 0.08 ± 0.03 0.01 ± 0.02 0.09 ± 0.01 0.07 ± 0.02 0.01 ± 0.02 
van’t Riet 
Conformation 
Number 
0.88 ± 0.08 0.92 ± 0.04 -0.04 ± 0.05 0.91 ± 0.02 0.90 ± 0.03 0.00 ± 0.02 
R50 4.45 ± 1.23 4.10 ± 1.14 0.35 ± 0.23 4.00 ± 0.37 3.98 ± 0.32 0.02 ± 0.21 
Table 2: True and predicted values for PTV statistics, homogeneity, van’t Riet conformation 
number, and the high dose spillage, R50. 
 
 
Figure 6: Box plots showing the dose difference statistics for the 8 test patients.  
A box plot of max and mean dose differences (True – Prediction) for the PTV and OARs for 
the test patient cases are shown in Figure 6. On average, the U-net model is biased to slightly 
over-predict the mean and max doses. A full list of average absolute differences for both the 
cross validation and test data can be found in Table 1. Overall, the cross validation error is 
slightly less than the test error. For the test data, the PTV, body and rectum maintain a 
prediction accuracy of within 3% error. The bladder has a low max dose error of 1.9% but a 
larger error in the mean dose of 4.2%. The femoral heads have higher max dose errors but 
reduced mean dose errors of under 3%. Overall, the model is capable of accurately predicting 
𝐷𝑚𝑎𝑥  and 𝐷𝑚𝑒𝑎𝑛 within 5.1% of the prescription dose. In addition all of the PTV related 
dosimetric statistics, dose conformity, and the dose spillage, 𝑅50, are very well predicted by 
the network as shown in Table 2. The PTV coverage, PTV 𝐷𝑚𝑎𝑥 , conformation number, and 
R50 have less than 1% error (calculated as |
𝑇𝑟𝑢𝑒−𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑
𝑇𝑟𝑢𝑒
| ∗ 100). 
 
 
Figure 7: Contours of the planning target volume (PTV) and organs at risk (OAR), true dose 
wash, predicted dose wash, and difference map of an example patient. 
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Figure 8: Example of typical dose volume histogram (DVH) comparing true dose and 
predicted dose for one patient. 
As a typical prediction example from the U-net model, Figure 7 shows the input contours, 
true and predicted dose washes, and a difference map of the two doses for one patient. On 
average, the dose difference inside the body was less than 1% of the prescription dose, 
shown in Table 1. Figure 8 shows the DVH of one of the example test patients. Visually on the 
DVH, one can see that the U-net tends to predict a similar PTV dose coverage with minimal 
errors in the dose prediction to the OARs. 
 
 
 Figure 9: Dice similarity coefficients, 
𝟐(𝑨 ∩ 𝑩)
𝑨+𝑩
, comparing isodose volumes between the true 
dose and predicted dose, ranging from the 0% isodose volume to the 100% isodose volume. 
The error in the graph represents 1 standard deviation. 
The plot of Dice similarity coefficients of isodoses is shown in Figure 9. Dice similarity 
coefficients range from 0 to 1, where 1 is considered a perfect match. The average Dice 
similarity coefficient for the test data is 0.91 and for the cross-validation data is 0.95, a 4% 
difference. The isodose volume similarity expresses slight decreases in the Dice coefficient 
near the 40% isodose volume. The loss in predictability at 40% is associated to the 
complicated details in the dose distribution along the beam paths in the normal tissue, which 
is generated during the fluence map optimization process. 
 Figure 10: Example dose predictions from the U-net model on several patients with vastly 
different geometries.  
Figure 10 shows some examples of dose prediction from the U-net on patients that have very 
diverse geometries. It can be visually seen that the U-net has learned to shape the dose based 
on the PTV and OARs sizes, locations, and shapes.  The finer details of the dose distributions 
further away from the PTV have been predicted by the deep network model with relative 
high accuracy. 
Contours True Dose Pred Dose 
A 
B 
C 
4 Discussion 
To our knowledge, this is the first fully 3D dose distribution prediction for prostate IMRT 
plans, thus making direct comparison to existing models difficult. The latest study by 
Shiraishi and Moore31 on knowledge based planning did investigate 3D dose prediction, but 
for prostate patients treated with VMAT. In addition, another cutting edge study by McIntosh 
and Purdie54 investigated 3D dose prediction using atlas regression forests. Because of the 
differing patient data base and treatment modalities/protocols, the results cannot be 
directly compared. It should be noted that Shiraishi and Moore’s average prediction error 
was less than 8% using their method on their patients, and McIntosh and Purdie’s study 
found the average Dice coefficient to be 0.88 (range is from 0.82 to 0.93). Therefore, our 
impression is that our predictive model is at least within the same ballpark as the cutting 
edge methods by these authors. 
The 88 clinical prostate patients acquired in this study used a similar set of 7 beam angles 
and criteria for treatment, giving rise to some uniformity to the data that made it ideal as a 
test bed to investigate the feasibility for dose prediction using a deep learning model. 
However, the current model architecture and data leave the U-net with several limitations. 
First, the model has currently learned to only predict the dose coming from approximately 
the same orientations, and may not be able to account for more intricate beam geometries. 
Secondly, the current model is unable to account for any physician preferences for predicting 
the dose, limiting the level of treatment personalization for the patient. For example, the 
model is unable to create a rectum-sparing plan or a bladder-sparing plan, at the will of the 
physician, for the same patient geometry. Furthermore, while training slice-by-slice had 
proven successful for coplanar cases, this method may not perform satisfactorily when 
performing dose prediction for non-coplanar plans. The deep network may have to 
understand the patient geometry in 3D if it were to start accounting for non-coplanar beam 
dose. Nevertheless, because the clinical prostate IMRT protocol is standardized, the current 
dose prediction model from this study can still be employed as a clinical guidance tool, where 
final tradeoff decisions will still be made by the physician and dosimetrist. By utilizing this 
model, the physician can immediately view the dose prediction and then convey how they 
desire for the plan to be changed to the dosimetrist. By already having a tangible plan to 
view, the dosimetrist can more readily apply the changes to make an acceptable plan earlier 
and ultimately reduce the total planning time. 
We plan to extend this study by building a deep learning model for learning dose predictions 
that is capable of handling a more diverse selection of non-coplanar beam orientations. We 
will investigate the extension of U-nets into the volumetric domain using V-nets55, in order 
to tackle dose prediction for non-coplanar radiotherapy plans, and add in dose constraint 
parameters into the model input to allow the prediction of dose based on the physician’s 
prescription, not only patient’s geometry. Furthermore, we will examine the addition of CT 
data and its effect on prediction accuracy. We expect the addition of such information to the 
model will greatly improve the prediction accuracy, and will investigate the impact of adding 
these types of information. 
5 Conclusion 
We have developed a novel application of the fully convolutional deep network model, U-net, 
for dose prediction. The model is able to take a prostate patient’s contours and then predict 
a dose distribution by abstracting the contours into local and global features.  Using our 
implementation of U-net we are able to accurately predict the dose of a patient, with average 
mean and max dose differences of all structures within 5.1% of the prescription dose. 
Isodose similarity evaluation reveals that the predicted dose isodose volumes match the true 
isodose volumes with the average Dice coefficient of 0.91. We plan to continue improving the 
model, by adding in dose prediction for non-coplanar beam arrangements and accounting 
for physician preference. The immediate application of the dose prediction model is to guide 
clinical plan optimization to reduce treatment planning time and to maintain high quality 
plans. The long-term objective is to incorporate the learning dose prediction model into an 
artificially intelligent radiation therapy treatment planner. 
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